Ken Griffin Relmada Therapeutics, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$2.3 - $4.36 $51,519 - $97,664	22,400 Added 79.43%	50,600 $163,000
Q2 2024 Aug 14, 2024	SELL	$2.93 - $4.94 $91,123 - $153,634	-31,100 Reduced 52.45%	28,200 $84,000
Q1 2024 May 15, 2024	SELL	$3.1 - $6.8 $58,900 - $129,200	-19,000 Reduced 24.27%	59,300 $275,000
Q4 2023 Feb 14, 2024	BUY	$2.45 - $4.22 $61,740 - $106,344	25,200 Added 47.46%	78,300 $324,000
Q3 2023 Nov 14, 2023	SELL	$2.48 - $3.79 $59,024 - $90,202	-23,800 Reduced 30.95%	53,100 $159,000
Q2 2023 Aug 14, 2023	BUY	$2.22 - $3.54 $98,346 - $156,822	44,300 Added 135.89%	76,900 $189,000
Q1 2023 May 15, 2023	SELL	$2.24 - $4.76 $140,896 - $299,404	-62,900 Reduced 65.86%	32,600 $73,000
Q4 2022 Feb 14, 2023	SELL	$2.17 - $35.84 $845,866 - $14 Million	-389,800 Reduced 80.32%	95,500 $333,000
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $6.59 Million - $13.3 Million	360,300 Added 288.24%	485,300 $18 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $80.1M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.